The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

The present invention relates to a method for improving the preparation of fermented black color ginseng containing functional ingredients at high contents based on safety, specifically to a novel Aspergillus niger KHNT-1 strain deposited with accession number KCTC14739BP; an improved process for preparing fermented black color ginseng through treatment with the strain, steaming utilizing pottery, and drying utilizing an LED dryer; fermented black color ginseng containing functional ingredients, ginsenosides Rg5, Rg3, and Rk1, and CK at high contents; and a composition for preventing, improving, or treating coronavirus infectious disease, the composition containing the fermented black color ginseng as an active ingredient.

As the fermented black color ginseng is prepared through fermentation using the novel Aspergillus niger KHNT-1 strain according to the present invention, steaming utilizing pottery as a steamer, and drying (fermentation) utilizing a medical LED as a dryer/fermenter, the method for improving the preparation of fermented black color ginseng is economical and safe since the preparation process takes 7 to 15 days and benzopyrene is not detected in the fermented black color ginseng, and the fermented black color ginseng contains ginsenosides Rg3, Rg5, and Rk1, and CK at high contents, and can be usefully utilized as a high value-added new drug raw material that is required to be contained at a high content per unit and in the field of high-functional food development.

The present invention relates to a method for improving the preparation of fermented black color ginseng containing functional ingredients at high contents based on safety, specifically to a novel Aspergillus niger KHNT-1 strain deposited with accession number KCTC14739BP; an improved process for preparing fermented black color ginseng through treatment with the strain, steaming utilizing pottery, and drying utilizing an LED dryer; fermented black color ginseng containing functional ingredients, ginsenosides Rg5, Rg3, and Rk1, and CK at high contents; and a composition for preventing, improving, or treating coronavirus infectious disease, the composition containing the fermented black color ginseng as an active ingredient.

As the fermented black color ginseng is prepared through fermentation using the novel Aspergillus niger KHNT-1 strain according to the present invention, steaming utilizing pottery as a steamer, and drying (fermentation) utilizing a medical LED as a dryer/fermenter, the method for improving the preparation of fermented black color ginseng is economical and safe since the preparation process takes 7 to 15 days and benzopyrene is not detected in the fermented black color ginseng, and the fermented black color ginseng contains ginsenosides Rg3, Rg5, and Rk1, and CK at high contents, and can be usefully utilized as a high value-added new drug raw material that is required to be contained at a high content per unit and in the field of high-functional food development.

The invention provides novel 3α-hydroxysteroid dehydrogenase mutants, sequences that code for these enzyme mutants, methods for producing the enzyme mutants, and the use thereof in enzymatic reactions of cholic acid compounds, and in particular in the production of ursodeoxycholic acid (UDCA). The invention further provides processes for the synthesis of UDCA using the enzyme mutants and the production of UDCA using recombinant microorganisms that have been subjected to multiple modifications.

Provided herein are high oleic oil compositions. Further provided herein are methods of producing high oleic oil compositions from microorganisms and applications thereof in end products, including, for example, polyols, polyurethane products, personal care products, and food products.

Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

Glucosyl stevia compositions are prepared from steviol glycosides of Stevia rebaudiana Bertoni. The glucosylation was performed by cyclodextrin glucanotransferase using the starch as source of glucose residues. The short-chain glucosyl stevia compositions were purified to >95% content of total steviol glycosides. The compositions can be used as sweetness enhancers, flavor enhancers and sweeteners in foods, beverages, cosmetics and pharmaceuticals.

The present disclosure provides recombinant Pichia pastoris, a construction method thereof, and use thereof in the efficient preparation of 15α-D-ethylgonendione, and belongs to the technical field of fermentation engineering. In the present disclosure, with Pichia pastoris as a host, 15α-steroid hydroxylase and glucose-6-phosphate dehydrogenase (G6PD) are simultaneously induced in a manner of intracellular enzyme production for the first time, and the Pichia pastoris whole-cell induction and catalysis mode is used to achieve the conversion of D-ethylgonendione with high substrate loading and high conversion rate.

The present disclosure provides recombinant Pichia pastoris, a construction method thereof, and use thereof in the efficient preparation of 15α-D-ethylgonendione, and belongs to the technical field of fermentation engineering. In the present disclosure, with Pichia pastoris as a host, 15α-steroid hydroxylase and glucose-6-phosphate dehydrogenase (G6PD) are simultaneously induced in a manner of intracellular enzyme production for the first time, and the Pichia pastoris whole-cell induction and catalysis mode is used to achieve the conversion of D-ethylgonendione with high substrate loading and high conversion rate.

Genetically-modified cell capable of producing UD CA, cholic acid, and/or another UDCA precursor comprising at least one heterologous polynucleotide encoding an enzyme involved in a metabolic pathway that converts sugar to UDCA, cholic acid, and/or another UDCA precursor. Method of making UDCA, cholic acid, and/or another UDCA precursor using such a cell. Use of UDCA or UDCA precursor produced using such a method for the manufacture of a medicament for the treatment of a disease or symptom of a disease. Medicament comprising UDCA or UDCA precursor made using such a method. Method of treating a disease or symptom of a disease comprising administering UDCA or a UDCA precursor made using such a method. Isolated nucleic acid encoding at least one enzyme involved in a metabolic pathway that converts sugar to UDCA, cholic acid, and/or another UDCA precursor. Vector comprising a nucleic acid encoding at least one enzyme involved in a metabolic pathway that converts sugar to UDCA, cholic acid and/or another UDCA precursor. Method of making a genetically-modified cell capable of synthesizing UDCA, cholic acid, and/or another UDCA precursor. Composition comprising UDCA or a UDCA precursor, a free acid or CoA thereof, or a pharmaceutically-acceptable derivative or prodrug thereof.